Bobby is a world-renowned scientist and physician and accomplished strategic and organizational leader with more than 25 years of experience in medicine and biotechnology. He is one of the principal scientific founders and current chief executive officer of Orchard Therapeutics, a global gene therapy leader recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe. Bobby has been a pioneer in gene therapy and the evolution of hematopoietic stem cell (HSC) gene therapy technology—including some of the first studies in patients with severe primary immune deficiencies—bringing it from some of the first studies in patients into late-stage clinical trials. His unparalleled expertise and deep relationships with key physicians and treatment centers around the world are integral to Orchard’s efforts to identify patients with metachromatic leukodystrophy (MLD) and other severe genetic conditions through targeted disease education, early diagnosis and comprehensive newborn screening.

Bobby was named to the inaugural TIME100 Health list in 2024, recognizing him as one of the world’s most influential individuals impacting human health. In addition to his role at Orchard, Bobby also serves as the chair of the board of directors at Eligo Biosciences, a privately-held biotech company expanding the scope of genetic medicines through gene-editing of the microbiome. He is also a venture partner at F-Prime, a global venture creation and investment firm with $4.5 billion under management.

Bobby is an honorary professor of pediatrics and immunology at the University College London (UCL) Great Ormond Street Institute of Child Health and has led multiple clinical trials that have shown that gene therapy can successfully correct the genetic defect in immune deficiencies. He studied medicine and surgery at Kings College in London before completing his Ph.D. at the UCL Great Ormond Street Institute of Child Health.

Frank brings more than 20 years of experience in the biopharmaceutical industry as an accomplished financial and business executive, with a proven track record of success in leading operations and strategy, corporate finance and commercialization at private and publicly traded biotechnology companies. Frank joined Orchard in 2018 as chief financial officer and chief business officer. Since that time, his role has expanded to president and chief operating officer of Orchard. He also continues to serve as the principal financial officer. In his capacities, Frank creates and drives strategies for overall value-creation and long-term growth of the company. He currently oversees key functional areas for the business, including but not limited to, finance, business development, commercial operations, corporate affairs and quality.

Frank previously served as president and chief operating officer of AMAG Pharmaceuticals (acquired in November 2020 by Covis Group), where he helped develop the business from a single product company in 2011 to one with a portfolio of commercial and development-stage products that generated more than $600 million in sales in 2017. During that time, Frank raised more than $1.8 billion in new capital to support AMAG’s growth strategy. Before joining AMAG, he served as chief operating officer and chief financial officer for Molecular Biometrics, Inc. Earlier in his career, Frank also served as chief executive officer for Critical Therapeutics and chief financial officer for Esperion Therapeutics. Each company completed its initial public offering in the U.S. during his tenure. Frank currently serves on the board of directors of Larimar Therapeutics and Spero Therapeutics.

Frank received his B.B.A. from the University of Michigan, Ann Arbor.

Laura is an accomplished biopharma executive with unique global experience that spans a broad range of functions, therapeutic areas and who carries deep experience of gene therapies, from bench to bedside.

In her role as chief medical officer at Orchard Therapeutics, Laura leads a skilled team of professionals in clinical development, medical affairs, diagnostics, newborn screening, and patient advocacy. She drives Orchard’s progress in early- and late-stage clinical development of the company’s next-in-line gene therapies for the treatment of Hurler, Sanfilippo, and NOD2 Crohn’s disease, the expansion of newborn screening for metachromatic leukodystrophy (MLD) and the medical leadership for the commercialization of OTL-200 for the treatment of early-onset MLD.

Prior to her appointment to CMO, Laura most recently served as vice president of clinical development, where she led the clinical sciences, operations, pharmacovigilance and bioanalytical assays departments at the company.

Laura joined Orchard Therapeutics in 2018, bringing experience from her roles in the rare diseases unit at GSK, working on their rare disease cell and gene therapy portfolio.

She studied at the University of Cambridge, earning a Bachelor of Medicine, Bachelor of Surgery (MB BChir) and a Bachelor’s in Natural Sciences. Before transitioning to industry, she built a successful career as a surgeon within the NHS, becoming a Member of the Royal College of Surgeons of England. Her contributions to pharmaceutical medicine have been recognized with a Fellowship of the Faculty of Pharmaceutical Medicine (FFPM), where she remains an active member, championing skills development and professional growth within the specialty.

Nicoletta has extensive experience leading all aspects of technical operations, including process and analytical development, manufacturing, supply chain, engineering and CMC lifecycle management. She joined Orchard Therapeutics from Novartis, where she held positions of increasing responsibility since 2004, most recently serving as global head of cell and gene therapies. In this role, Nicoletta led multidisciplinary international teams responsible for the end-to-end technical development, manufacturing and project management of several gene and cell therapies modalities, including lentiviral, adeno-associated virus (AAV), stem and CAR-T cell processes, from concept to commercialization. She also oversaw the integration of the CAR-T teams and AveXis’ AAV technical capabilities into Novartis’ technical R&D. Previously, Nicoletta was global head of technical development novel biologic entities and cell and gene therapies where she was responsible for the early phase development of biologics and gene therapies. Her broad industry experience encompasses global leadership in the development and manufacturing of sterile drug products and devices and approvals of several commercial assets.

A medicinal chemist by training, Nicoletta began her career in the biopharmaceutical industry as a formulation scientist at Pfizer. She earned her Ph.D. in pharmaceutical technologies from the University of Pavia in Italy. She is a registered pharmacist and member of the UK Royal and Italian Pharmaceutical societies.

Fulvio leads the company’s discovery and translational research activities. In this capacity he will be responsible for expanding the company’s pipeline into larger indications.

He joined Orchard Therapeutics from Smart Immune where he served as chief scientific officer. Previously, Fulvio was senior vice president of translational science at Audentes Therapeutics in San Francisco, where he was responsible for advancing the company’s pipeline from discovery to clinical development overseeing molecular biology, in vivo pharmacology, bioinformatics, and bioanalytics. Prior to joining Audentes, Fulvio was chief scientific officer of Genethon in Évry, France from 2012 to 2017 where he led the development of a robust pipeline of gene therapy programs for blood, liver, and neuromuscular diseases. Earlier in his career, he held various positions at the Center for Regenerative Medicine of the University of Modena, Molmed SpA, Genera SpA, and the San Raffaele-Telethon Institute of Gene Therapy in Milan, Italy.

Fulvio is a member of the Scientific Advisory Board for Kriya Therapeutics. He is also a member of the European Molecular Biology Association, past member of the Board of the American Society of Gene and Cell Therapy and a member of the editorial board of many international journals in the fields of genetics, molecular biology and gene therapy. Fulvio earned a Ph.D. in medical genetics at the University of Rome School of Medicine and has published more than 200 articles in major international journals. He also serves as Professor of Molecular Biology at the University of Modena and Reggio Emilia in Modena, Italy.

Chris Northey is a dynamic and results-driven biopharmaceutical executive with deep expertise overseeing a wide array of strategic initiatives, complex projects and drug development programs at every stage of their life cycle.

In his current role, Chris is responsible for overseeing corporate strategy, program leadership and management, business development, and communications. Chris leads teams in the planning, execution, and delivery of high-impact programs that drive operational efficiency, enhance corporate governance, and boost innovation in drug development to help fully unlock the transformative potential of HSC gene therapy for people living with severe genetic diseases worldwide. His ability to balance scientific rigor with business acumen has been instrumental in optimizing portfolio value and performance while ensuring alignment with corporate strategy.

Prior to Orchard Therapeutics, Chris held positions of increasing responsibility at Takeda, most recently serving as program director of company integration, designing and coordinating the incorporation of a cell therapy biotech following its acquisition. He has experience across different modalities and multiple therapeutic areas, including rare, cardiovascular and metabolic diseases having led large global development programs from research through to late phase development.

Chris holds a Bachelor of Science in Biochemistry from the University of Edinburgh. In addition to his technical expertise, Chris is a strong advocate for fostering collaborative, high-performance teams known for their commitment to continuous improvement and professional development.